Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2024-11-09 Declaration of Voting R…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Results of a meeting held on November 7, 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly mentions 'Form 6-K' and refers to the 'Annual General Meeting of Shareholders' held on November 7, 2024. It details that shareholders voted on and approved proposals described in the Proxy Statement. Since the document reports the results of the shareholder vote from the AGM, it aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions the AGM, the core content is the outcome of the voting process, not the presentation materials (AGM-R) or the proxy solicitation itself (PSI). The filing is a Form 6-K, which is a general regulatory filing, but DVA is more specific to the content described (voting results).
2024-11-09 English
Results of a meeting held on November 7, 2024
Report Publication Announcement Classification · 1% confidence The document is extremely short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6k08112024_isa.pdf*". This structure indicates that the current document is an announcement or cover page for an attached filing, rather than the full report itself. The reference to '6k' (likely an SEC Form 6-K, which is used by foreign private issuers for material events) and the presence of Israeli regulatory information (Israel Securities Authority, MAGNA) suggest it's a regulatory disclosure. Since the document's primary function here is to announce the publication of another report, it fits the definition of a Report Publication Announcement (RPA). It is not a comprehensive report like 10-K or IR.
2024-11-09 English
Immediate Report of adjourned meeting to be held on November 7,2024
Proxy Solicitation & Information Statement Classification · 1% confidence The document text explicitly contains voting instructions, proposals for electing directors, approving option extensions, approving restricted share unit grants, and approving amendments to executive agreements. The presence of terms like 'PROXY', 'PROPOSAL NO.', 'Board of Directors', 'shareholders', and voting options ('FOR', 'AGAINST', 'ABSTAIN') strongly indicates this is a document soliciting shareholder votes for a general meeting. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI). While it relates to an AGM (Proposal 1 mentions 'annual general meeting'), the format is the solicitation document itself, not the meeting materials (AGM-R) or the final results (DVA).
2024-10-31 English
Immediate Report of adjourned meeting to be held on November 7,2024
AGM Information Classification · 1% confidence The document explicitly states it is an 'Immediate Report of Meeting' concerning the 'holding an adjourned meeting' and details the agenda items, which include re-electing directors and approving option term extensions. This content is directly related to the proceedings and agenda of a shareholder meeting. Since the document details the agenda and decisions to be voted upon at an Annual General Meeting (AGM), the most appropriate classification is AGM Information (AGM-R). It is not a proxy statement (PSI) as it is reporting on the meeting itself, nor is it a DVA (Declaration of Voting Results) as the meeting is scheduled for the future (07/11/2024).
2024-10-31 English
The Annual Meeting will be reconvened on Thursday, November 7, 2024
AGM Information Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the SEC by a Foreign Private Issuer. The content discusses the adjournment of the 'Annual General Meeting of Shareholders' (AGM) scheduled for October 31, 2024, and its rescheduling to November 7, 2024. Since the document relates directly to the proceedings and scheduling of the AGM, the most appropriate classification is AGM Information (AGM-R). Although Form 6-K is a general filing, the specific subject matter dictates the classification over the general 'RNS' fallback.
2024-10-31 English
The Annual Meeting will be reconvened on Thursday, November 7, 2024
Report Publication Announcement Classification · 1% confidence The document is very short (1767 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k31102024_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a 6-K filing, which is typically an 'Other Report' under SEC rules, often used by foreign private issuers). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). Since the document is announcing the release of a filing, RPA is the most appropriate classification over RNS or the underlying report type.
2024-10-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.